Skip to content

Event Registration and Agenda

The promotional presentation at 20.15 contains a ▼Paxlovid® (nirmatrelvir/ritonavir) promotional video from Pfizer Ltd. Paxlovid prescribing information and adverse event reporting information can be found at the bottom of this web page as well as at the meeting itself.

18.30 Tea/coffee

19.00 Welcome and introduction (Johnathan Laird)

19.15 Question Time


Laura Wilson: Director for Scotland Royal Pharmaceutical Society

Maurice Hickey: Pharmacists Defence Association (PDA) Head of Policy Scotland

Matt Barclay: Director of Operations Community Pharmacy Scotland

Professor Anne Boyter: Professor of Learning and Teaching Strathclyde Institue of Pharmacy and Biomedical Sciences

20.15 Promotional presentation

20.30 Meeting Close

We need this to confirm your registration as this event is for healthcare professionals only.
Please tell us a your question. If selected you will get the opportunity to put put your question directly to the panel on the night. You are welcome to suggest multiple questions.
Go to our homepage to read our privacy policy.
Go to our homepage to read our privacy policy.

PAXLOVID is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. (1) Paxlovid has a Conditional Marketing Authorisation (CMA) in Great Britain. A CMA means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.

Reference: (1): Paxlovid Great Britain SmPC.

Paxlovid Prescribing Information for Great Britain HCPs: